Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Overview of attention for article published in Annals of the Rheumatic Diseases, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 2 news outlets
twitter: 10 X users
patent: 1 patent

reddit: 1 Redditor
guideline: 1 clinical guideline source
podcasts: 1 podcast

Readers on

mendeley: 124 Mendeley

So far, Altmetric has seen 12 X posts from 10 X users, with an upper bound of 51,070 followers.

RT @ARD_BMJ: Pooled post-hoc efficacy and safety data for Anifrolumab in #SLE show favorable BICLA responses at 52 weeks and comparable saf…

Sustained #anifrolumab response in active #SLE over 1 yr but not sure measuring IFN gene signature will discriminate responders, article may suggest otherwise.

RT @ARD_BMJ: Pooled post-hoc efficacy and safety data for Anifrolumab in #SLE show favorable BICLA responses at 52 weeks and comparable saf…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.